CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor and scientific conferences: 2024 Wells Fargo Healthcare Conference Chief Executive Officer and President, Ram Aiyar, Ph.D., and Chief Financial Officer, Vineet Agarwal, will participate ...

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD. New data for KRRO-110 shows approximately 60% editing efficiency and greater than 60µM ...

Core Insights - Korro Bio, Inc. is advancing its development candidate KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), showcasing promising preclinical data [1][3] - The company is on track to submit a regulatory filing for a first-in-human study of KRRO-110 in AATD patients in the second half of 2024 [3] Preclinical Data - KRRO-110 demonstrated approximately 60% editing efficiency and increased total AAT protein levels to greater than 60µM at week 13, with previous data showing efficacy up to week 9 [2][6] - The study included a non-human primate surrogate test article, supporting species translation towards human dose projections [2] AATD Overview - AATD is an inherited genetic disorder primarily caused by a mutation in the SERPINA1 gene, with over 95% of severe cases being homozygous for the PiZ mutation [4] - The condition can lead to severe lung and liver diseases, affecting an estimated 3.4 million individuals globally [4] Company Background - Korro Bio focuses on developing a new class of genetic medicines using its proprietary RNA editing platform, aiming to provide precise and transient single base edits [5] - The company is based in Cambridge, Massachusetts, and is leveraging established regulatory pathways for oligonucleotide drugs to bring its medicines to patients [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 One Kendall Square, Building 600-700, Suite 6-401 Cambridge, MA 02139 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39062 Korro B ...

Exhibit 99.1 Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024, and provided an update on its recent progress and anticipated milestones. • Appointed Dr. Kemi Olug ...

Appointed Kemi Olugemo, M.D., FANN as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024 and provided an update on its recent progress and anticipated milestones. On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in ...

Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Proceeds fund interim readout in the second half of 2025 and FIH study completion in 2026 for KRRO-110 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Korro Bi ...

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress Exhibit 99.1 - On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024 - Demonstrated the versatility of Korro's RNA editing platform by generating de-novo protein variants via multiple targets in non-human primates (NHPs) - Demonstrated greater than 50% editing using GalNAc conjugates in the liver with subcutaneous administration ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-39062 Korro Bio, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39062 FREQUENCY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2324450 (State or other ...